📢 DDReg Knowledge Capsule – Episode [11]while the COVID-19 pandemic accelerated mRNA visibility, its scope now includes cancer immunotherapies, treatments for genetic and metabolic disorders, and regenerative medicine, with the global market projected for significant growth. The text also outlines both the key benefits of mRNA, such as speed and versatility, and the inherent challenges, including stability issues, delivery complexity, and high manufacturing costs. Finally, the document details the regulatory landscape for mRNA therapeutics, highlighting frameworks from the U.S. FDA, the EMA, and the WHO, and asserts DDReg’s role in helping companies navigate these complex approval pathways.